Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma

BACKGROUND: The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years. We evaluated the cost-effectiveness of this t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Qian, Yushen, Maruyama, Satoshi, Kim, Haju, Pollom, Erqi L, Kumar, Kiran A, Chin, Alexander L, Harris, Jeremy P, Chang, Daniel T, Pitt, Allison, Bendavid, Eran, Owens, Douglas K, Durkee, Ben Y, Soltys, Scott G
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2017
Sujets:
Clinical Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5716167/
https://ncbi.nlm.nih.gov/pubmed/28666368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox121
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires